Author:
Fallon Lara,Jones Thomas V
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference5 articles.
1. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
2. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
3. European Medicines Agency . Xeljanz (tofacitinib): summary of product characteristics, 2020. Available: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf [Accessed 10 Jul 2020].
4. European Medicines Agency . EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots, 2020. Available: https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf [Accessed 10 Jul 2020].
5. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献